MedPath

study on [F-18] FDG and [F-18] FLT in the assessment of malignant tumors

Not Applicable
Conditions
malignant tumors
Registration Number
JPRN-UMIN000029524
Lead Sponsor
Department of Diagnostic Radiology,Medical Hospital Tokyo Medical and Dental University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

1. patients with blood sugar level over 200mg/dl when they take [F-18] FDG PET/CT 2. patients who are pregnant or have high possibility of pregnancy 3. patients who are unable to give an appropriate consent in terms of mental and legal point of view

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
to show improved detectability of primary malignant tumors and their metastases or reccurrences, and the efficacy in the assessment of treatment response and prognosis using [F-18] FLT PET/CT.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath